Radius Health, Inc. (NASDAQ:RDUS) has been given a $85.00 price objective by analysts at Canaccord Genuity in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price target points to a potential upside of 97.79% from the stock’s current price.

RDUS has been the topic of a number of other reports. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, May 22nd. Maxim Group set a $24.00 target price on shares of Radius Health and gave the stock a “sell” rating in a report on Wednesday, May 24th. HC Wainwright restated a “buy” rating and issued a $66.00 target price (down previously from $71.00) on shares of Radius Health in a report on Friday, March 24th. Finally, BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $56.83.

Radius Health (NASDAQ RDUS) traded down 9.35% during midday trading on Monday, reaching $42.97. 2,692,561 shares of the company traded hands. Radius Health has a one year low of $31.58 and a one year high of $59.88. The stock’s 50 day moving average is $38.94 and its 200 day moving average is $40.08. The company’s market capitalization is $1.86 billion.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by $0.14. During the same quarter last year, the company posted ($0.94) EPS. On average, equities analysts anticipate that Radius Health will post ($4.42) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/07/17/radius-health-inc-nasdaqrdus-given-a-85-00-price-target-by-canaccord-genuity-analysts.html.

In other Radius Health news, major shareholder Growth N. V. Biotech purchased 40,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was bought at an average price of $36.25 per share, with a total value of $1,450,000.00. Following the completion of the purchase, the insider now directly owns 4,998,799 shares of the company’s stock, valued at approximately $181,206,463.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech purchased 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was acquired at an average cost of $33.91 per share, with a total value of $2,543,250.00. Following the purchase, the insider now directly owns 4,765,399 shares of the company’s stock, valued at $161,594,680.09. The disclosure for this purchase can be found here. Insiders purchased 498,400 shares of company stock valued at $17,411,288 in the last ninety days. 15.00% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. Creative Planning raised its stake in shares of Radius Health by 77.8% in the second quarter. Creative Planning now owns 29,665 shares of the biopharmaceutical company’s stock worth $1,342,000 after buying an additional 12,980 shares during the last quarter. Bank of Nova Scotia acquired a new stake in shares of Radius Health during the first quarter worth approximately $1,933,000. Point72 Asset Management L.P. acquired a new stake in shares of Radius Health during the first quarter worth approximately $1,256,000. FNY Partners Fund LP raised its stake in shares of Radius Health by 40.5% in the first quarter. FNY Partners Fund LP now owns 5,900 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 1,700 shares during the last quarter. Finally, Credit Suisse AG raised its stake in shares of Radius Health by 146.9% in the first quarter. Credit Suisse AG now owns 92,180 shares of the biopharmaceutical company’s stock worth $3,563,000 after buying an additional 54,844 shares during the last quarter.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.